OOIR: Observatory of International Research

Papers

(The median citation count of Cancer Journal is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Toxicities From Antibody-Drug Conjugates	86
Social Drivers of Cancer Risk and Outcomes Among African American Men	44
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer	37
PET Imaging of Metabolism, Perfusion, and Hypoxia	25
Oncology Physician Workforce Diversity	21
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer	21
Individualizing Therapy for Malignant Gliomas	20
Building a Bridge to Equity in Health and Health Care in Cancer Care	19
Health Care Policy and Disparities in Health	19
Clinical Evidence Generation During a Pandemic	19
Stereotactic Body Radiation Therapy	17
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer	17
Melanoma—Modern Treatment for Metastatic Melanoma	15
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies	15
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer	13
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia	13
The Principles and Practice of PARP Inhibitor Therapy	13
Metastatic Melanoma Treatment in Special Populations	12
Evaluation of the Prognostic Role of Liver Metastases on Patient Outcomes	12
Diversity in Cancer Care	12
Nonoperative Management for Rectal Cancer	12
Antibody Drug Conjugates in Multiple Myeloma	11
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma	11
Germline Predisposition to Myelodysplastic Syndromes	11
Prostate Cancer, Race, and Health Disparity	11

Primary Prevention of Cancer	10
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer	10
Clinical Targeting of Altered Metabolism in High-Grade Glioma	10
Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy	10
Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas	9
Overlooked and Damaging Impact of Structural Racism and Implicit Bias on US Health Care	9
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer	9
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes	9
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia	9
Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer	8
Advances in Stereotactic Body Radiation Therapy for Lung Cancer	8
Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia?	8
DNA Damage Repair Inhibitors—Combination Therapies	8
Rectal Cancer—The Only Constant Is Change	8
Overview of the Management of Higher-Risk Myelodysplastic Syndromes	7
New Metabolomic Insights Into Cancer	7
Introduction	7
Menopausal Hormone Therapy and Breast Cancer	7
Updates in the Management of Uveal Melanoma	7
Supportive Care for Patients With Myelodysplastic Syndromes	7
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia	7
The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance	7
Effective Personalization of Stereotactic Radiosurgery for Brain Metastases in the Modern Era	7
Telehealth and Technology	7
The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer	7
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease	6
Discovery of Natural Products for Cancer Prevention	6
How Far We’ve Come	6
Survival of the Fittest	6
Role of the Microbiome in Immunotherapy of Melanoma	6
Neurosurgical Advances for Malignant Gliomas	6
Short- and Long-term Repercussions of Vancomycin on Immune Surveillance and the Efficacy of Antitumor Treatments	6
Evolving Landscape of Antibody Drug Conjugates in Lymphoma	6
Impact of Precision Medicine in Oncology	6
Telemedicine and cancer care: Barriers and strategies to optimize delivery: Erratum	6
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma	6
Hormone Replacement Therapy After Breast Cancer	6
Telemedicine Across the Cancer Care Continuum	5
Current State of Cell Therapies for Genitourinary Malignancies	5
Molecular Imaging of Steroid Receptors in Breast Cancer	5
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development	5
Estrogen for the Treatment and Prevention of Breast Cancer	5
Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms	5
The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment	5
Telemedicine and Cancer Care	5
What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma?	5
The Challenges and Future of Immunotherapy for Gliomas	5
Repurposing Drugs for Cancer Prevention	5
Gene Expression Profiles in Cancers and Their Therapeutic Implications	5
STING Agonists in Head and Neck Squamous Cell Carcinoma	4

Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer	4
Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases	4
The Clinical Value of Plasma Epstein-Barr Virus DNA as a Tumor Marker in Nasopharyngeal Carcinoma: Prognostic? Yes, But How Can We Best Use It?	4
Severe Lymphopenia Predicts Poorer Survival in Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiation	4
What to Eat for Cancer Prevention	4
Impact of Precision Medicine in Oncology	4
Local Excision for Early-Stage Rectal Adenocarcinomas	4
Radiopharmaceuticals for Cancer Diagnosis and Therapy	4
The Gut Microbiome and Pancreatic Cancer Development and Treatment	4
With Our Powers Combined	4
The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation	4
Antibody-Drug Conjugates in Myeloid Leukemias	4
Beyond the COVID-19 Pandemic	4
Telemedicine and Burnout—How Enhancing Operational Support Can Improve Digital Health Tools	3
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia	3
Effective Image Communication of Hormone Replacement Therapy Risks and Benefits	3
Digital Health for Oncological Care	3
Chimeric Antigen Receptor T-Cell Therapy	3
Concerns About Compounded Bioidentical Menopausal Hormone Therapy	3
Evolution of Response-Based Radiotherapy for Hepatocellular Cancer	3
The Utility of Interim Positron Emission Tomography Imaging to Inform Adaptive Radiotherapy for Head and Neck Squamous Cell Carcinoma	3
Neoantigen-Specific T Cells in Adoptive Cell Therapy	3
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?	3
Nuclear Medicine Cancer Care—Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer	3
Advancements in Understanding and Preventing Obesity-Related Colon Cancer	3
Epidemiology and Pathogenesis of Myelodysplastic Syndrome	3
Updates in Classification of Myelodysplastic Syndrome	3
PARP Inhibitors in Pancreatic Cancer	3
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches	3
Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer	3
Stereotactic Body Radiotherapy in Oligomestatic/Oligoprogressive Sarcoma	3
The Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances	3
Management of Low-Grade Gliomas	3
Introduction	3
Adoptive Cell Therapy for Advanced Solid Tumors	3
Circulating Biomarkers in Glioblastoma	3
Antibody-Drug Conjugates and Tissue-Agnostic Drug Development	3